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Abstract
A strong gender bias is seen in many autoimmune diseases including systemic lupus 
erythematosus (SLE). To investigate the basis for the female preponderance in SLE, we have been 
studying BALB/c mice in which B cells express the R4A heavy chain of an anti-DNA antibody in 
association with an endogenous light chain repertoire (R4Atg mice). In unmanipulated mice, 
approximately 5% of B cells express the R4A transgene. R4Atg mice do not spontaneously 
develop elevated serum titers of anti-DNA antibodies. Administration of either estradiol (E2) or 
prolactin (Pr) results in escape from tolerance of autoreactive B cells, expressed as an increase in 
transgene-expressing B cells and elevated serum titers of anti-DNA antibodies. We previously 
demonstrated that autoreactive B cells maturing in an estrogenic milieu develop as marginal zone 
(MZ) B cells; when these same B cells mature in the presence of increased prolactin, they develop 
as follicular (Fo) B cells. To determine the long term consequence of this differential maturation 
of DNA-reactive B cells, we treated R4Atg BALB/c mice with E2 or Pr for 6 weeks until serum 
titers of anti-DNA antibody were high, at which time hormonal exposure was discontinued. In E2-
treated mice, the anti-DNA titers remained high even 3 months after discontinuation of hormone 
exposure. Nascent B cells underwent normal tolerance induction, but existing autoreactive MZ B 
cells persisted and continued to secrete autoantibody. In contrast, Pr caused only a short-term 
increase in anti-DNA antibody titers. By 3 months after cessation of hormone treatment, serum 
anti-DNA antibody titers and B cell subsets were indistinguishable from those in placebo (P) 
treated mice. These findings suggest that autoantibody responses are sustained for variable lengths 
of time depending on the B cell subset producing the autoantibodies. This observation may be 
relevant to understanding the heterogeneous presentation of patients with SLE and to the design of 
therapies targeting speci?c B-cell populations in autoimmune disease.
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1. Introduction
Immature B cells leave the bone marrow and migrate to the spleen as transitional B cells. If 
they escape negative selection, they mature into marginal zone (MZ) or follicular (Fo) B 
cells. In mice MZ B cells have an IgMhighIgDlowCD21highCD23− phenotype, express high 
levels of Toll-like receptors (TLRs), and participate in both T cell-independent and T cell-
dependant immune responses [1–7]. MZ B cells express immunoglobulin variable genes that 
are, in general, unmutated and many express polyreactive B cell receptors (BCRs) [1,5,8]. In 
contrast to MZ B cells, Fo B cells have an IgMint IgDhighCD21lowCD23high phenotype, 
express more oligospeci?c BCRs, participate in T cell-dependent responses and undergo 
affinity maturation in a germinal center response [9,10]. MZ and Fo B cells also differ with 
respect to the kinetics of antibody production with MZ B cells displaying faster kinetics of 
antibody secretion [7]. Both MZ and Fo B cells have been shown to participate in the anti-
DNA response in murine models of systemic lupus erythematosus (SLE) [11,12].
In an effort to understand the selection and maturation of DNA-reactive B cells in SLE, we 
have been studying B cell maturation in R4Atg BALB/c mice, which harbor a transgene 
(Tg) encoding the IgG2b heavy chain of an anti-DNA antibody [13]. The R4A heavy chain 
pairs with endogenous light chains, generating a spectrum of antibodies, some with no 
binding to DNA, others with low, and some with high af?nity binding to DNA [14–16] 
(Table 1). Despite expression of an IgG2b heavy chain, B cells mature normally and 
tolerance is maintained in these mice by negative selection of high af?nity anti-DNA B cells 
[13].
Both E2 and Pr have been reported and to contribute to autoimmunity in general and to SLE 
pathogenesis in particular [17–29]. Sex hormones have been implicated in risk for 
developing SLE and in disease activity although the data are controversial [30]. Estrogen, in 
particular, has been extensively studied as the ratio of females to male with onset of SLE 
increasing from 3 to 1 before puberty to 9 to 1 after puberty [31]. Clinical epidemiologic 
studies have suggested that the use of oral contraception increases the risk of SLE [32]. In 
contrast, the SELENA study of the safety of estrogen in women with SLE failed to 
demonstrate that the use of oral contraception increased the frequency of disease flares [33]. 
The data are further complicated by the demonstration that the use of hormone replacement 
therapy did increase the number of flares [34].
Animal models of SLE-like disease also provide divergent data. Some, like NZB/W mice, 
display a clear female bias. Moreover, studies in NZB/W mice have demonstrated a 
dramatic delay in disease onset and reduction in disease severity in female mice following 
ovariectomy or administration of estrogen receptor antagonists [35,36]. In contrast, others, 
such as MRL/lpr mice, have a less profound female bias and estrogen exacerbates the 
autoantibody-mediated glomerulonephritis of MRL/lpr mice while it diminishes vasculitis 
[37].
Prolactin levels have also been reported to be elevated in a high percentage of patients with 
a variety of autoimmune diseases [38]. In particular, they are elevated in approximately 25% 
of SLE patients. While a relationship between disease activity and prolactin level has not 
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been clearly established in human SLE, antibodies to prolactin appear to correlate with 
lower disease activity [39]. Small clinical trials in SLE patients suggest a therapeutic effect 
of bromocriptine, but large scale, definitive trials have not been performed [40–42]. 
Administration of prolactin to NZB/W mice accelerates disease while treatment with 
bromocriptine, a drug that inhibits prolactin secretion, can retard disease progression [43].
Both estrogen and prolactin affect numerous cells within the immune system [38,44]. To 
understand their impact on disease expression, it is important to isolate effects on particular 
cell lineages. We have been studying the impact of estrogen and prolactin on B cells using 
the R4Atg BALB/c mouse. We use this model as it allows us to isolate the effects of 
estrogen and prolactin on B cell biology in the absence of a large number of inflammatory 
factors that can exacerbate or diminish the effects of these hormones. This model also 
allowed us to remove hormone and observe the impact of hormone withdrawal without the 
confounding effects of the inflammatory cytokines present in spontaneous models of SLE. 
When R4Atg BALB/c mice are treated with E2 sufficient to sustain serum levels at the 
concentration achieved during the luteal phase of the estrus cycle, B cells making high 
affinity anti-DNA antibodies survive negative selection and mature as MZ B cells [45]. In 
contrast, when R4Atg BALB/c mice are treated with Pr to cause a doubling of serum Pr 
concentration, high affinity autoreactive B cells mature as Fo B cells [46]. Previously we 
demonstrated that both the MZ and Fo B cells express identical BCRs showing the 
differentiation pathway for a specific B cell can be determined by hormonal milieu [47]. 
This observation provided an opportunity to study the long-term survival and activation of B 
cells with identical BCRs having either an MZ or Fo phenotype.
In this study, we report that the antibody response of MZ B cells is of longer duration than 
that of Fo B cells. Autoreactive B cells are present in Pr-treated mice only while Pr levels 
are high. In contrast, the persistence of autoreactive MZ B cells is not dependent on the 
continued presence of E2. These findings have potential implications for understanding 
clinical SLE and the response to therapy as the time frame for falls in autoantibody titers are 
likely to depend on the B cell subset responsible for production of the autoantibody.
2. Materials and methods
2.1. Mice and hormone treatment
R4Atg BALB/c mice, which have been described previously [13], were bred in a specific 
pathogen-free barrier facility. All animal studies were approved by the Institutional Animal 
Care and Use Committee (IACUC). Mice were implanted subcutaneously with 60-day time-
release pellets containing placebo (P), E2 (17 β-estradiol; 0.18 mg) or Pr (6 mg) (Innovative 
Research of America). The E2 pellets lead to a constant serum level of 75–100 pg/ml over a 
60-day period [16]. The Pr pellet leads to a two-fold increase in serum Pr levels to 20–35 
ng/ml [46]. Prior to implanting hormone pellets, all mice were ovariectomized to eliminate 
fluctuations in endogenous E2 levels. After 6 weeks of treatment, the E2, Pr or P pellets 
were removed and the mice were followed for an additional 12 weeks. Serum was obtained 
before the start of treatment and at biweekly intervals thereafter. To examine the level of 
proteinuria, urine was also collected at the beginning of treatment and every two weeks 
thereafter. Kidneys were examined at the end of the study as described below.
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2.2. Autoreconstitution
R4Atg mice were implanted with E2 pellets for 6 weeks and subsequently underwent 
sublethal irradiation with 600 rads of gamma irradiation [48]. Mice were allowed to 
reconstitute for 12 weeks after irradiation and were then analyzed for B cell subsets. Urine 
was collected to assess proteinuria. IgG deposition in the kidneys was examined as 
described.
2.3. Cell surface staining and flow cytometry
Splenocytes from P- and hormone-treated R4Atg mice were isolated and stained with 
antibodies to cell surface markers. B cell subsets were analyzed by flow cytometry using an 
LSRII instrument (Becton Dickinson). The monoclonal antibodies employed were B220 
(clone 7G6), CD21 (clone 7G6), CD23 (clone B3B4), AA4.1 and γ2b (clone R12-3); all 
were obtained from BD Pharmingen except for AA4.1 (eBioscience). B cell subsets were 
identified as transitional T1 (B220+AA4.1hiCD21lowCD23−), T2 (B220+AA4.1hiCD 
21hiCD23hi), MZ (B220+AA4.1−CD21hiCD23−) and Fo (B220+AA4.1−CD21lowCD23hi). In 
reconstitution experiments, CD24 staining was used to identify transitional B cell subsets.
2.4. Single cell RT-PCR and repertoire analysis
Immature (B220+IgG2b+AA4.1+) and mature (B220+IgG2b+AA 4.1−) tg-expressing B cells 
were sorted from P- and hormone-treated R4Atg mice as single cells into 96-well PCR 
plates using a FACS Aria cell sorter (BD Biosciences). cDNA was prepared as described 
previously [49]. Single cell PCR of Ig kappa light chain variable region genes of tg-
expressing B cells was accomplished in two rounds as described [50]. The first round was 
performed using the universal Vκ 5′ primer 
(5′GGCTGCAGSTTCAGTGGCAGTGGRTCWGGRAC3′) and the constant region primer 
Cκ (Cκ1), (5′TGGATGGGTGGGAAGATG3′) and the second, nested round with Vκ and 
Cκ (Cκ2) (5′AAGATGGATACAGTTGGT3′) primers. The PCR products were subjected to 
exo-SAP treatment (USB Biochemicals) and the kappa light chains were sequenced using 
the Cκ2 primer (Genewiz Inc.). The samples were analyzed for Vκ-Jκ family usage using 
the NCBI BLAST program (www.ncbi.nlm.nih.gov/IgBlast).
2.5. ELISAs
Half-well plates (Costar) were dry-coated with calf thymus DNA (100 mg/ml, Sigma), 
blocked with 2% bovine serum albumin (BSA) and subsequently incubated with dilutions of 
serum obtained from P- or hormone-treated R4Atg mice. Anti-dsDNA antibody titer was 
measured with an IgG2b-specific secondary antibody coupled to alkaline phosphatase (AP) 
and phosphate substrate tablets, as previously described [51].
2.6. ELISpot assay
The frequency of anti-dsDNA antibody secreting B cells was evaluated by ELISpot analysis 
[16]. Briefly, Immulon 2HB 96-well plates (Thermo LabSystems) were coated with 100 
μl/ml sonicated calf thymus DNA. Splenocytes from P- or hormone-treated R4Atg mice 
were added to the plates in serial dilution and incubated for 12 h at 37 °C followed by 
biotin-conjugated anti-mouse IgG (1:600 dilution, Southern Biotechnology) and alkaline 
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phosphatase (AP)-conjugated streptavidin (Southern Biotechnology). The plates were 
developed with 5-bromo-4-chloro-3-indolyl phosphate substrate (Sigma Aldrich) and spots 
were counted under a dissecting microscope.
2.7. Glomerular IgG deposition
IgG deposition in the glomeruli of R4Atg mice was evaluated as described previously [51]. 
Kidneys were formalin fixed and paraffin embedded. 10 uM sections were stained with 
biotinylated anti-mouse IgG antibody and developed with an AP ABC detection kit (Vector 
Laboratories). IgG deposition in the glomeruli was visualized under a Zeiss microscope at 
X5 and X20 magnifications. The total number of glomeruli and glomeruli with IgG 
deposition in three different microscopic fields was determined for each kidney section. At 
least three mice were analyzed in each group.
2.8. Analysis of proteinuria
Proteinuria was measured using Bayer reagent strips (Bayer) according to the 
manufacturer’s specifications and expressed as mg/dL. Five mice in each group were 
examined for these studies.
2.9. Statistical analysis
All results are expressed as mean ± SD. Student’s t test (two-tailed) was used to compare 
differences between groups and Fisher’s exact test was used to analyze kappa chain 
repertoire.
3. Results
3.1. Long-term activation of MZ B cells
We have shown previously that exposure to E2 or Pr leads to the protection from negative 
selection of high affinity anti-DNA B cells in R4Atg BALB/c mice and to their subsequent 
activation as MZ [45] or Fo B cells [46], respectively. Interestingly, the same B cells can 
mature to either subset, depending on hormone exposure demonstrating that hormonal 
milieu as well as antigenic specificity, contributes to B cell differentiation [47]. Because MZ 
B cells are reported to be more long-lived than Fo B cells [52], we assessed the duration of 
antibody response after hormone levels were no longer elevated. We exposed 
ovariectomized R4Atg mice to E2 for 6 weeks until serum titers of anti-DNA antibody were 
high, and then removed hormone pellets to eliminate the source of hormonal stimulation and 
determined the duration of the anti-DNA response. Surprisingly, as long as 3 months after 
removal of the E2 pellet, anti-DNA titers remained high and DNA-reactive B cells were 
present in high number in the spleen (Fig. 1A and B).
In previous studies using single cell analysis of light chains expressed in association with the 
R4A heavy chain, we have identified the light chains that confer high or low affinity DNA 
binding (Table 1). Moreover, we have shown that E2 treatment leads to a light chain 
repertoire with an increased frequency of VJ sequences that confer high affinity to DNA, 
especially Vκ1-Jκ1 and Vκ9/10-Jκ5 light chains, in tg-expressing B cells. In contrast, DNA-
reactive B cells of P-treated mice exhibit a predominance of Vκ4/5-Jκ5, Vκ1-Jκ5 and 
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Vκ21-Jκ1 light chains that confer low affinity DNA-reactivity [47,50]. We were interested 
to see whether the tg-expressing B cells of E2-treated R4Atg mice continued to express VJ 
genes encoding high-affinity DNA-reactive antibodies even 3 months after cessation of 
exposure to E2. Hence, we performed repertoire analysis of the kappa light chains from the 
γ2b+ mature B cells in R4Atg mice that received E2 for 6 weeks and were subsequently 
without hormone exposure for 12 weeks. We observed a persistent increase in the frequency 
of light chains that confer high affinity DNA-binding in these mice compared to mice 
treated with P for 6 weeks and subsequently followed for 12 additional weeks (Table 2).
To confirm that the antibodies present in the serum of R4Atg mice after cessation of E2 
exposure were potentially pathogenic, we examined mice for the presence of proteinuria. 
E2-treated mice continued to exhibit increased proteinuria (Fig. 1C). We also examined the 
kidneys of these mice and found glomerular IgG deposition (Fig. 1D and E). Thus, renal IgG 
deposition was present even 3 months subsequent to discontinuation of E2 exposure.
3.2. Continued expansion of MZ B cells subsequent to cessation of E2
In previous studies, a sustained exposure of R4Atg mice to E2 resulted in a 2-fold increase 
in tg-expressing γ2b B cells as well as a doubling of MZ B cells in the spleen [30]. We 
wanted to determine whether the alteration in B cell subsets persisted even 3 months after 
discontinuation of E2. In R4Atg mice that were implanted with either E2 or P pellets for 6 
weeks followed by removal of pellets, the total numbers of B cells were similar (29.06–
38.12 × 106 vs. 33.27–39.68 × 106, respectively). R4Atg mice with E2 implanted pellets 
exhibited no difference in transitional B cell populations but displayed a sustained increase 
in MZ B cells (Fig. 2A and B). Because we have previously shown that all γ2b-expressing B 
cells express the tg [13], we analyzed γ2b-expressing B cells and observed a sustained 
increase in their number (Fig. 2C). These observations demonstrate that E2-induced 
activation of MZ B cells persisted for at least as long as 12 weeks in a milieu devoid of E2.
3.3. Persistence of autoreactive MZ B cells induced by E2
To distinguish whether immature or transitional tg-expressing B cells were continuing to 
differentiate to MZ B cells, due perhaps to a persisting change in the bone marrow or in 
splenic stromal cells, we subjected R4Atg mice that had been treated for 4 weeks with E2 to 
irradiation and analyzed the reconstituted B cell populations. The B cell reconstituted mice 
displayed no elevation in anti-DNA antibody titers (Fig. 3A). B cell subsets were similar to 
those observed in P-treated mice; there was no expansion of tg-expressing or MZ B cells 
(Fig. 3B). Thus, there was no evidence for a long-term E2-induced alteration in B cell 
microenvironment to support the continued maturation of autoreactive MZ B cells. Rather, 
prolonged survival of the autoreactive MZ cells led to a persistent elevation in autoantibody 
titers in E2-treated mice.
3.4. Short-term activation of autoreactive follicular B cells
Unlike E2, Pr induces anti-DNA B cells to become Fo B cells in R4Atg mice [46]. We asked 
whether autoantibody titers were sustained even after cessation of Pr exposure. R4Atg mice 
were implanted for 6 weeks with Pr or P pellets; the pellets were removed and mice were 
followed an additional 12 weeks. In contrast to E2, Pr caused only a short-term increase in 
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anti-DNA antibody titer. Anti-DNA titers declined by 6 weeks after removal of the Pr pellet 
to levels observed in R4Atg mice given P pellets (Fig. 4A). At 12 weeks after cessation of Pr 
exposure, there was no detectable increase in DNA-reactive B cells (Fig. 4B). Pr- and P-
treated mice displayed no difference in the level of proteinuria or glomerular Ig deposition 
(Fig. 4C–E). Repertoire analysis displayed no increase in the frequency of light chains 
conferring high-affinity DNA-binding in mature B cells of Pr-treated mice at 12 weeks 
following discontinuation of Pr treatment (Table 3), demonstrating that the high affinity 
DNA-reactive B cells were no longer present. Consistent with this observation, by three 
months after cessation of Pr treatment, B cell subsets and the number of γ2b-expressing B 
cells were the same as in P-treated mice (Fig. 5). These observations are consistent with 
other studies showing that the Fo B cell compartment is not long lived and needs constant 
replenishment from an immature B cell population [52].
4. Discussion
Elegant molecular studies have demonstrated the presence of both estrogen and prolactin 
receptors on numerous lineages of immune cells [38,53]. The effects of these hormones on 
gene expression and cell function are both pro- and anti-inflammatory [44]. We have been 
interested in understanding how to improve B cell-targeted therapy in SLE. While 
autoantibodies are critical to clinical manifestations of disease, we have yet to develop 
clinically proven effective therapies that target B cell survival, selection or activation 
[54,55]. This may reflect, in part, an inadequate understanding how to identify the B cell 
subset that harbors the autoreactive population in individual patients and how to target a 
specific B cell subset. Indeed, focusing on the subset that harbors the autoreactive B cells 
might permit us to design therapies that are less broadly immunosuppressive.
We have previously shown that the same DNA-reactive B cell can mature as either MZ or 
Fo cells depending on hormonal milieu. In this study, we demonstrate that the duration of 
autoantibody response depends on the differentiation phenotype of the autoreactive B cells.
We performed these studies in a non-spontaneously autoimmune mouse harboring a heavy 
chain tg for an anti-DNA antibody. This model allows us to identify the effects of hormones 
on B cell function, independent of the numerous immune perturbations that are present in 
spontaneous mouse models of SLE. The effects we observe, however, may nonetheless 
represent either direct effects of estrogen or prolactin on B cells or indirect effects, 
downstream of hormonal effects on other cell lineages. We observed a persistent effect of 
E2 exposure on serum anti-DNA antibody titers in R4Atg mice due to the long-term survival 
of MZ DNA-reactive B cells. Thus, the persistence of high titers of autoantibodies does not 
necessarily imply the presence of long lived plasma cells arising from the Fo B cell subset. 
We have previously shown that E2 has direct effects on maturing B cells, protecting them 
from BCR-mediated apoptosis [56]. E2 has also been shown to enhance the level of BAFF 
production by myeloid cells [47,50,57], which promotes B cell maturation to a MZ 
phenotype [58]. E2 also reduces T cell production of IL-2, potentially leading to a reduced 
population of T regulatory cells [59]. Finally, E2 enhances BCR-mediated apoptosis and 
augments p202b expression, which protects the B cell from TLR-mediated activation [60]. 
Therefore, both direct and indirect effects of E2 on B cells can lead to the survival of 
Jeganathan et al. Page 7
J Autoimmun. Author manuscript; available in PMC 2015 April 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
autoreactive B cells, their differentiation to an MZ phenotype and their activation. Once high 
E2 levels were no longer present there were no apparent residual effects of E2 exposure on 
B cell maturation, but the survival of DNA-reactive MZ B cells did not require persistently 
high levels of E2. Thus, E2 can cause a sustained autoantibody response. It is of interest that 
some lupus patients have been shown to metabolize E2 to its highly estrogenic forms [61]. 
These individuals may be those in whom DNA-reactivity resides within the MZ B cell 
subset.
Pr exposure also alters B cell maturation through direct and indirect effects on B cells. It has 
been demonstrated that transitional B cells have highest expression of Pr receptor and that 
levels of receptor expression associate with autoreactivity [62]. Pr has also been shown to 
upregulate CD40 ligand on T cells, a T cell phenotype that has been reported in SLE patients 
[63]. Blockade of the CD40:CD40 ligand interaction can reduce SLE disease progression 
dramatically in NZB/W mice, confirming the importance of CD40 ligand in SLE 
pathogenesis [64,65]. While a clinical trial in SLE patients was terminated prematurely due 
to an unanticipated increase in thrombotic events, early evidence suggested therapeutic 
efficacy [66]. Interestingly, elevated levels of Pr are found in approximately 25% of lupus 
patients [23–29], although it has not been investigated whether these patients express high 
levels of CD40 ligand. The current study demonstrates that the B cells that develop in a high 
prolactin environment become short-lived plasma cells and there must be continuous 
maturation of transitional DNA-reactive B cells to Fo B cells to maintain a population of 
autoantibody secreting B cells. It is tempting to speculate that individuals with elevated Pr 
levels may be those who exhibit fluctuating levels of anti-DNA antibodies.
Here we highlight the importance of knowing the B cell subset responsible for autoantibody 
production, and targeting it appropriately. It has been demonstrated that type 1 interferon as 
well as Pr will cause B cells to become short-lived plasma cells [67]. In contrast, BAFF 
induces selective differentiation of MZ B cells [55]. In mice, a CD20 targeted antibody is 
more effective at depleting Fo B cells than MZ B cells, although it is not clear the same is 
true in humans [68,69]. BAFF blockade prevents the maturation of immature B cells, and 
impairs survival of short-lived plasma cells before affecting survival of MZ B cells [70,71]. 
Thus, effects of BAFF blockade on autoantibody titers would be expected to occur over a 
longer period of time if MZ B cells are responsible for the autoreactivity and over a shorter 
period of time if autoantibodies derive from short-lived plasma cells. Blockade of 
CD40:CD40 ligand interaction might affect activation of both Fo B cells and MZ B cells but 
would not affect already activated MZ B cells [72].
Thus, it is apparent that therapy must be tailored to address the underlying B cell subset 
responsible for autoreactivity and the mechanism involved in B cell differentiation to that 
subset. Models such as R4Atg mice will allow an exploration of the effects of therapy on 
specific B cell subsets. Since hormone levels can clearly affect B cell differentiation 
pathways, it would be instructive to determine hormone levels in patients participating in 
clinical trials to determine if there are patient cohorts more likely to benefit from a particular 
therapy and if there are hormonal modulations that might enhance therapeutic efficacy.
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5. Conclusion
Our study reveals a sharp contrast in autoantibody responses expressed by MZ and Fo B 
cells. This finding may be pertinent in human SLE, in which patients display heterogeneity 
in their autoantibody responses as well as in their response to therapy. An understanding of 
the B cell subsets that contribute to autoreactivity in patients will greatly facilitate targeted 
therapies.
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Fig. 1. 
Persistence of anti-DNA reactivity and IgG deposition in R4Atg mice following 
discontinuation of E2 exposure. R4Atg mice that had been exposed to E2 for 6 weeks and 
then followed for 12 weeks displayed (A) elevated levels of anti-DNA antibody, (B) an 
increase in DNA-reactive splenic B cells, (C) proteinuria and (D and E) glomerular IgG 
deposition. P values were determined by Student’s t test.
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Fig. 2. 
Alterations in E2-induced B cell subsets persist following withdrawal of E2. The transitional 
(T1 and T2), mature (MZ and Fo) and the transgenic B cell populations were analyzed by 
flow cytometry. On left is a representative set of plots. (A) The transitional B cell subsets of 
E2-treated mice 3 months after removal of the E2 pellet were indistinguishable from those 
of P-treated mice. (B) There was continued expansion of MZ B cells and a persistent 
increase in the percentage of tg-expressing B cells. MZ B cells were identified as 
B220posCD21highCD23negAA4.1low/neg and transitional B cells were identified as 
B220posCD21lowAA4.1high (T1) and B220posCD21highAA4.1hgh (T2). The results shown 
represent mean ± SD of 5 mice in each group. Student’s t test was used to determine the 
significance between the groups.
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Fig. 3. 
Anti-DNA antibodies and altered B cell subsets after cessation of E2 and B cell 
reconstitution. R4Atg mice were treated for 6 weeks with E2 and subsequently irradiated 
with a sublethal dose of 600 rads of gamma irradiation. 12 weeks after irradiation and 
lymphoid reconstitution, serum anti-DNA antibody response was determined by ELISA. (A) 
The anti-DNA antibody levels were no longer elevated in these mice (week 18). (B) All B 
cell subsets were present at a normal frequency: transitional T1 (B220posCD21lowAA4.1high) 
and T2 (B220posCD21hiAA4.1high), MZ (B220posCD21highCD23negAA4.1low/neg) and Fo 
(B220posCD21negCD23hi AA4.1low/neg). An expansion of tg+ B cells was not observed. The 
results are expressed mean ± SD of 5 mice in each group.
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Fig. 4. 
DNA reactivity in R4Atg mice subsequent to withdrawal of Pr. Six to 8 week-old R4Atg 
mice were implanted with Pr or P pellets for 6 weeks following which the pellets were 
removed. After 12 weeks, the mice were analyzed for (A) serum anti-DNA reactivity; (B) 
DNA-reactive B cells; (C) proteinuria and (D and E) glomerular Ig deposition. At least 5 
mice were used in each group for the experiments.
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Fig. 5. 
B cell subsets in R4Atg mice following cessation of Pr exposure. In R4Atg mice were 
treated with Pr or P for 6 weeks followed by removal of the pellet. Transitional T1 and T2 B 
cells, MZ and Fo B cell populations were similar. No differences in the numbers of tg-
expressing B cells were observed, as determined by the Student’s t test, in 5 mice per group.
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Table 1
Relative affinities of DNA-reactive B cells from R4Atg BALB/c mice.
-Vκ-Jκ usage Relative Affinitya Reference
Vκ1A-Jκ1 9.1 × 10−8 [15, 16]
Vκ1-Jκ5 4.5 × 10−9 [16]
Vκ1A-Jκ4 4.2 × 10−6 [15]
Vκ21-Jκ1 2.2 ×10−6 [16]
Vκ21-Jκ2 9 × 10−6 [16]
a
The relative affinity of the R4A H chain paired with each L chain was determined in previous studies by inhibition ELISA.
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Table 2
Frequency of high affinity DNA-reactive B cells in R4Atg mice treated with P or E2 following which time, 
treatment was discontinued for 12 weeks.
P E2
Transitional 11/125 (8.8%) 8/107 (14.9%)
Mature 9/112 (8%) 29/131 (23%)*
Fisher’s exact test was used to analyze the significance between the P- and the E2- treated groups.
*denotes p < 0.05.
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Table 3
Frequency of high affinity DNA-reactive B cells in R4Atg mice treated with P or Pr for 6 weeks following 
which time treatment was discontinued for 12 weeks.
P Pr
Transitional 3/56 (5.4%) 4/63 (6.4%)
Mature 4/60 (6.7%) 7/71 (9.9%)
No significant differences were observed between the groups.
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